h-index: 7     i10-index: 6

Document Type : Original Research Article


1 Department of Biochemistry, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran

2 Bahaman Faculty of Medical Sciences, Bahaman, Iran


Introduction: Voxelotor, also known as GBT 440, binds to the alpha cleft in HbS tetramers and promotes the stability of the relaxed or oxygenated state of HbS. This process hinders the conformational change of the HbS tetramers into the deoxygenated state. Voxelotor prevents interactions between HbS tetramers in the deoxygenated state, ultimately inhibiting the polymerization of HbS tetramers and resulting in significant clinical improvements, particularly in raising hemoglobin levels in patients. In this study, we have explored the use of herbal compound models, such as rosmarinic acid and compounds with similar structures that exhibit high binding affinity to Voxelotor's hemoglobin binding site.
Materials and methods: The molecular model of hemoglobin (PDB: 5E83) was initially obtained from the RCSB PDB database. In addition, we collected 453 ligand models with structural similarity to rosmarinic acid from the PubChem database. To prepare these models for molecular docking, we utilized the Molegro Virtual Docker tool. Subsequently, we used the SwissADME web tool to predict the physicochemical properties and pharmacokinetics of these compounds. Results: We investigated the affinity and binding site of 453 compounds similar to rosmarinic acid on the hemoglobin model (PDB: 5E83). Our focus was on the alpha cleft between two alpha chains of the hemoglobin model (PDB: 5E83). The results showed that most compounds had molecular weights above 500 daltons, and some exhibited acceptable hydrophobicity. Furthermore, their solubility in aqueous solutions was good. None of the compounds were able to cross the blood-brain barrier or have gastrointestinal absorption. However, they did have varying inhibitory effects on CYP2C9 cytochromes. The skin penetration rate was generally low.
Conclusion: Through our study, we identified three compounds (CID: 162739375, CID: 141386569, and CID: 24015539) with promising potential for further research. These compounds demonstrated high binding affinity to the hemoglobin model, favorable dissolution and digestive absorption rates, as well as suitable hydrophobicity, making them ideal candidates for continued laboratory investigation


Main Subjects


©2024 The author(s). This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit: http://creativecommons.org/licenses/by/4.0/


Sami Publishing Company remains neutral concerning jurisdictional claims in published maps and institutional affiliations.


Sami Publishing Company

[1] Abdulmalik O., Safo M.K., Lerner N.B., Ochotorena J., Daikhin E., Lakka V., Santacroce R., Abraham D.J. Asakura T., Characterization of hemoglobin bassett (α94Asp→ Ala), a variant with very low oxygen affinity. American Journal of Hematology, 2004, 77:268 [Crossref], [Google Scholar], [Publisher]‎
[2] Gopalsamy A., Aulabaugh A.E., Barakat A., Beaumont K.C., Cabral S., Canterbury D.P., Casimiro-Garcia A., Chang J.S., Chen M.Z., Choi C., Dow  R.L., PF-07059013: a noncovalent modulator of hemoglobin for treatment of sickle cell disease. Journal of Medicinal Chemistry, 2020, 64:326 [Crossref], [Google Scholar], [Publisher]‎
[3] Henry  E.R., Metaferia  B., Li  Q., Harper  J., Best  R.B., Glass  K.E., Cellmer  T., Dunkelberger  E.B., Conrey  A., Thein  S.L. Bunn  H.F., Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin, Blood, The Journal of the American Society of Hematology, 2021, 138:1172 [Crossref], [Google Scholar], [Publisher]‎
[4] Xu  M., An G., A Pharmacometrics Model to Characterize a New Type of Target-Mediated Drug Disposition (TMDD)–Nonlinear Pharmacokinetics of Small-Molecule PF-07059013 Mediated By Its High-capacity Pharmacological Target Hemoglobin With Positive Cooperative Binding, The AAPS Journal, 2023, 25:41 [Crossref], [Google Scholar], [Publisher]‎
[5] Nadeem M., Imran M., Aslam Gondal T., Imran A., Shahbaz  M., Muhammad Amir  R., Wasim Sajid M., Batool Qaisrani T., Atif M., Hussain G., Salehi  B., Therapeutic potential of rosmarinic acid: A comprehensive review, Applied Sciences, 2019, 9:3139 [Crossref], [Google Scholar], [Publisher]‎
[6] National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 5281792, Rosmarinic acid. Retrieved March 27, 2024 [Publisher]‎
[7] Oksenberg D., Dufu K., Patel M.P., Chuang C., Li Z., Xu Q., Silva‐Garcia A., Zhou C., Hutchaleelaha A., Patskovska L., Patskovsky Y., GBT 440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half‐life in a murine model of sickle cell disease, British Journal of Haematology, 2016, 175:141 [Crossref], [Google Scholar], [Publisher]‎
[8] Kim S., Thiessen P.A., Bolton E.E., Chen J., Fu G., Gindulyte A., Han L., He J., He S., Shoemaker B.A., Wang J., PubChem substance and compound databases, Nucleic Acids Research, 2016, 44:1202 [Crossref], [Google Scholar], [Publisher]‎
[9] Bitencourt-Ferreira G., de Azevedo W.F., Molegro virtual docker for docking. Docking screens for Drug Discovery,2019, 149 [Crossref], [Google Scholar], [Publisher]‎
[10] Daina A., Michielin O., Zoete V., SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Scientific Reports, 2017, 7:42717 [Crossref], [Google Scholar], [Publisher]‎
[11] Daina A., Michielin O., Zoete V., iLOGP: a simple, robust, and efficient description of n-octanol/water partition coefficient for drug design using the GB/SA approach. Journal of Chemical Information and Modeling, 2014, 54:3284 [Crossref], [Google Scholar], [Publisher]‎
[12] Daina A., Zoete V., A boiled‐egg to predict gastrointestinal absorption and brain penetration of small molecules,  ChemMedChem, 2016, 11:1117 [Crossref], [Google Scholar], [Publisher]‎
[13] Fujikawa  M., Nakao  K., Shimizu R., Akamatsu M., QSAR study on permeability of hydrophobic compounds with artificial membranes, Bioorganic & Medicinal Chemistry, 2007, 15:3756 [Crossref], [Google Scholar], [Publisher]‎
[14] Ramirez D.A., Federici M.F., Altamirano J.C., Camargo A.B., Luco  J.M., Permeability data of organosulfur garlic compounds estimated by immobilized artificial membrane chromatography: correlation across several biological barriers. Frontiers in Chemistry, 2021, 9:690707 [Crossref], [Google Scholar], [Publisher]‎
[15] Yousefi  R., Mokarmian S., Jamshidi A., Efficacy of Beta-Secretase-1 Enzyme Inhibitors in Alzheimer's Disease, Journal of Advanced Pharmacy Research, 2023, 7:243 [Crossref], [Google Scholar], [Publisher]‎
[16] Yousefi R., Mokarmian R., Jamshidi A., Molecular Docking of Pepstatin (A) and Compounds with Structural Similarity to the Molecular Model of Human BACE-1 Enzyme,  Journal of Advanced Pharmacy Research, 2023, 7:181 [Crossref], [Google Scholar], [Publisher]‎
[17] Yousefi R., Binding of curcumin near the GBT440 binding site at the alpha cleft in the sickle cell hemoglobin model [Pdb ID: 1NEJ],  Journal of advanced Biomedical and Pharmaceutical Sciences, 2024, 70 [Crossref], [Google Scholar], [Publisher]‎